The Comparison of Intraocular Pressure between the Treatment for Osteoarthritis in Aging Patients with Glucosamine Sulfate and without Glucosamine Sulfate Intraocular Pressure after Glucosamine Intake
Article Sidebar
Main Article Content
Abstract
Background: Glucosamine is widely prescribed for osteoarthritis (OA) treatment because of its effectiveness and safety profile. However, there was a study reported about glucosamine associated with the increase of intraocular pressure (IOP) in patients with glaucoma. The effect of IOP elevation in non-glaucomatous population is still inconclusive.
Purpose: To compare the change of IOP between the treatment for osteoarthritis with and without glucosamine sulfate in aging patients.
Methods: This is a prospective comparative study. OA patients were enrolled and divided into two groups depending on the indications for glucosamine sulfate treatment. Twenty patients were treated with oral glucosamine sulfate and twenty patients were treated with other medications. IOP was measured before glucosamine sulfate treatment, 2, 4, 8, 12, 24 weeks after glucosamine sulfate treatment, and 2 weeks after stopping glucosamine sulfate treatment. The change of IOP was compared between the two groups. Statistical analysis used 2-way repeated-measures analysis of variance with a 2-tailed t-test.
Results: Forty patients were identified and met inclusion criteria. The mean age was 67.24+8.45 years. There was no difference in patients' characteristics between groups except age which the glucosamine group was younger (63.33 vs 70.75, p=0.005). In the glucosamine group (n=20), baseline IOP was 13.96±1.82 mmHg. IOP increased significantly from baseline in 2 weeks after starting glucosamine supplementation (+0.93±1.21 mmHg, p=0.005). There was no statistical change of IOP compared to baseline in other visits including the visit after glucosamine withdrawal. In the non-glucosamine group, baseline IOP was 14.16±2.57 mmHg. There was no change of IOP in any visit.
Conclusion: IOP was significantly increased at 2 weeks after taking glucosamine sulfate. There was no statistical change of IOP compared to baseline in other visits including the visit after glucosamine withdrawal.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Kongtharvonskul J, Anothaisintawee T, McEvoy M, et al. Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: a systematic review and network meta-analysis. Eur J Med Res 2015;20:24.
Nagaoka I, Igarashi M, Sakamoto K. Biological activities of glucosamine and its related substances. Adv Food Nutr Res 2012;65:337–52.
Clegg D, Reda D, Harris C, et al. Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. N Engl J Med 2006; 354:795-808.
Sibbritt D, Adams J, Lui C, et al. Who Uses Glucosamine and Why? A Study of 266,848 Australians Aged 45 Years and Older. PLoS ONE. 2012;7:e41540.
Deal CL, Moskowitz RW. Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate and collagen hydrolysate. Rheum Dis Clin North Am 1999;25:379–95.
Richy F, Bruyere H, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003;163:1514–22.
Singh JA, Wilt T, MacDonald R. Chondroitin for osteoarthritis. Cochrane Database Syst Rev 2006;1:CD005614.
Acott TS, Westcott M, Passo MS, Van Buskirk EM. Trabecular meshwork glycosaminoglycans in human and cynomolgus monkey eyes. Invest Ophthalmol Vis Sci 1985;26:1320–9.
Knepper PA, McLone DG. Glycosaminoglycans and outflow pathways of the eye and brain. Pediatr Neurosci 1986;12:240–51.
Murphy R, Ketzler L, Rice R, et al. Oral Glucosamine Supplements as a Possible Ocular Hypertensive Agent. JAMA Ophthalmol 2013;131:955.
Esfandiari H, Pakravan M, Zakeri Z, Ziaie S, Pakravan P, Ownagh V. Effect of glucosamine on intraocular pressure: a randomized clinical trial. Eye (Lond) 2017;31:389-94.
Yuenyongviwat V, Kiddee W, Tangtrakulwanich B. Effect of glucosamine sulfate on intraocular pressure in patients with knee osteoarthritis: A prospective randomized controlled trial. J Fr Ophthalmol 2019;42:711-5.
Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Early Manifest Glaucoma Trial Group Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003;121:48–56.
De Voogd S., Ikram M.K., Wolfs R.C. Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study. Ophthalmology 2005; 112:1487-93.
Johnson KA, Hulse DA, Hart RC, Kochevar D, Chu Q. Effects of an orally administered mixture of chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate on synovial fluid chondroitin sulfate 3B3 and 7D4 epitope in a canine cruciate ligament transection model of osteoarthritis. Osteoarthritis Cartilage 2001;9:14–21.
McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000;283:1469–75.
Sawitzke AD, Shi H, Finco MF, Dunlop DD, Harris CL, Singer NG et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 2010;69:1459–64.
Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005;2:CD002946.
Berggren L, Vrabec F. Demonstration of a coating substance in the trabecular meshwork of the eye and its decrease after perfusion experiments with different kinds of hyaluronidase. Am J Ophthalmol 1957;44:200-8.
Southren AL, Gordon GG, l'Hommedieu D, Ravikumar S, Dunn MW, Weinstein BI. 5 beta-Dihydrocortisol: possible mediator of the ocular hypertension in glaucoma. Invest Ophthalmol Vis Sci 1985;26:393-5.
Zimmerman LE. Demonstration of hyaluronidase-sensitive acid mucopolysaccharide in trabecula and iris in routine paraffin sections of adult human eyes; a preliminary report. Am J Ophthalmol 1957;44:1-4.
Jones R 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 2006;17:163–7.
Francois J. Corticosteroid glaucoma. Ann Ophthalmol 1977;9:1075-80.